Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China

NEXT STORY
Global Large Volume Wearable Injectors Market Outlook to 2030 with Competitive Analysis on 400+ Players
PREV STORY
iTeos Therapeutics Announces Pricing of Initial Public Offering
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab

author_avatar
NASDAQ Market News

Europe Immunochemistry Market (2018 to 2027) – Regional Analysis and Forecasts by Application; Product; End User, and Country

author_avatar
NASDAQ Market News

Terveystalo’s occupational health services to expand: Terveystalo acquires the occupational health operations from Welfare District of Forssa

author_avatar
NASDAQ Market News